Aspira Pathlab & Diagnostics share news and announcements
BSE: 540788Healthcare ServicesSmall Cap
Share price at the BSE close on 23 Oct 2026. Previous close ₹123.45.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹130 Cr3,082nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 23 May 2026
- 10.6
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 12 Aug 2026
- −3.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 12 Aug 2026
- −4.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 23 May 2026
- 0.11
- Volume, BSEVolume. Shares traded on the last trading day.
- 352
Aspira Pathlab & Diagnostics share news and announcements
520 announcements, routine notices left out, newest first. Page 8 of 11.
Aug 2020
29 Aug · Intimation To Stock Exchanges Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")
29 Aug · Announcement under Regulation 30 (LODR)-Raising of Funds
25 Aug · Board meeting
Meeting on 29 Aug 2020: annual general meeting
Jul 2020
31 Jul · Disclosure Under Regulation 30 Read With Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
28 Jul · Management
28 Jul · Outcome Of Meeting Of The Board Of Directors Held On July 28, 2020, Pursuant To Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015.
23 Jul · Board meeting
Meeting on 28 Jul 2020: quarterly results and preferential issue of shares20 Jul · Shareholding for the Period Ended June 30, 2020
Shareholding Pattern for the Period Ended June 30, 2020. For more details, kindly Click ....20 Jul · Statement Of Investor Complaints For The Quarter Ended June 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 011 Jul · Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligation &Disclosure Requirements) Regulations, 2015
Jun 2020
13 Jun · Outcome Of Meeting Of The Board Of Directors Of Aspira Pathlab & Diagnostics Limited
11 Jun · Disclosure Of Material Impact Of COVID - 19 Pandemic On The Company Under Regulation 30 Read With Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 And SEBI Advisory Vide Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/84 Dated May 20, 2020
8 Jun · Board meeting
Meeting on 13 Jun 2020: audited results
May 2020
5 May · Certificate Under Regulation 40(9) Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended March 31, 2020
5 May · Certificate Under Regulation 40(9) Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended March 31, 2020
1 May · Compliance Certificate Under Regulation 7(3) Of SEBI (Listing Obligation & Disclosure Requirements) Regulations 2015 For The Half Year Ended March 31, 2020
Apr 2020
24 Apr · Shareholding for the Period Ended March 31, 2020
Shareholding Pattern for the Period Ended March 31, 2020. For more details, kindly Click ....20 Apr · Statement Of Investor Complaints For The Quarter Ended March 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Feb 2020
4 Feb · Contact Details Of KMP For Reporting Of Material Events
4 Feb · Outcome Of Meeting Of The Board Of Directors Of Aspira Pathlab & Diagnostics Limited, Pursuant To Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('Listing Regulations').
4 Feb · Outcome Of Meeting Of The Board Of Directors Of Aspira Pathlab & Diagnostics Limited, Pursuant To Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('Listing Regulations').
4 Feb · Outcome Of Meeting Of The Board Of Directors Of Aspira Pathlab & Diagnostics Limited, Pursuant To Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('Listing Regulations').
Jan 2020
29 Jan · Compliance Under Regulation 47 Of The SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015
27 Jan · Board meeting
Meeting on 4 Feb 2020: quarterly results17 Jan · Shareholding for the Period Ended December 31, 2019
Shareholding Pattern for the Period Ended December 31, 2019. For more details, kindly Click ....13 Jan · Statement Of Investor Complaints For The Quarter Ended December 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Dec 2019
7 Dec · Shareholding for the Period Ended November 27, 2019
Shareholding Pattern for the Period Ended November 27, 2019. For more details, kindly Click ....7 Dec · Shareholding for the Period Ended November 22, 2019
Shareholding Pattern for the Period Ended November 22, 2019. For more details, kindly Click ....2 Dec · Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligation &Disclosure Requirements) Regulations, 2015 For The Half Year Ended September 30,2019